CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma

被引：0

作者：

Jagannath, Sundar ^{[1
]}

Martin, Thomas ^{[2
]}

Usmani, Saad ^{[3
]}

Berdeja, Jesus ^{[4
]}

Jakubowiak, Andrzej ^{[5
]}

Agha, Mounzer ^{[6
]}

Cohen, Adam ^{[1
,7
]}

Deol, Abhinav ^{[8
]}

Htut, Myo ^{[9
]}

Lesokhin, Alexander ^{[3
]}

Munshi, Nikhil ^{[10
,11
]}

O'Donnell, Elizabeth ^{[12
]}

Jackson, Carolyn ^{[13
]}

Yeh, Tzu-Min ^{[13
]}

Banerjee, Arnob ^{[14
]}

Zudaire, Enrique ^{[14
]}

Madduri, Deepu ^{[13
]}

DelCorral, Christopher ^{[15
]}

Pacaud, Lida ^{[15
]}

Lin, Yi ^{[16
]}

机构：

[1] Mt Sinai Med Ctr, New York, NY USA

[2] Univ Calif San Francisco, San Francisco, CA USA

[3] Mem Sloan Kettering Canc Ctr, New York, NY USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Univ Chicago, Chicago, IL USA

[6] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[7] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA USA

[8] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[9] City Hope Comprehens Canc Ctr, Duarte, CA USA

[10] Dana Farber Canc Inst, Boston, MA USA

[11] Harvard Med Sch, Vet Affairs Boston Healthcare Syst, Boston, MA 02115 USA

[12] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA

[13] Janssen Res & Dev, Raritan, NJ USA

[14] Janssen Res & Dev, Spring House, PA USA

[15] Legend Biotech USA Inc, Somerset, NJ USA

[16] Mayo Clin, Rochester, MN USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-275

引用

页码：S187 / S187

页数：1

共 50 条

[21] Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
Martin, Tom
Usmani, Saad Z.
Schecter, Jordan M.
Vogel, Martin
Jackson, Carolyn C.
Deraedt, William
Tian, Hong
Yeh, Tzu-min
Banerjee, Arnob
Pacaud, Lida
Garrett, Ashraf
Haltner, Anja
Cameron, Chris
Van Sanden, Suzy
Diels, Joris
Valluri, Satish
Samjoo, Imtiaz A.
CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (10) : 1779 - 1788
[22] Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
Martin, Tom
Usmani, Saad Z.
Schecter, Jordan M.
Roccia, Tito
Jackson, Carolyn C.
Deraedt, William
Yeh, Tzu-Min
Banerjee, Arnob
Pacaud, Lida
Garrett, Ashraf
Bartlett, Meaghan
Haltner, Anja
Van Sanden, Suzy
Diels, Joris
Valluri, Satish
Samjoo, Imtiaz A.
CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (01) : 81 - 89
[23] Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study (vol 398, pg 314, 2021)
Berdeja, J. G.
Madduri, D.
Usmani, S. Z.
LANCET, 2021, 398 (10307): : 1216 - 1216
[24] Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Richardson, Paul G.
Jagannath, Sundar
Moreau, Philippe
Jakubowiak, Andrzej
Raab, Marc S.
Facon, Thierry
Vij, Ravi
White, Darrell
Reece, Donna E.
Benboubker, Lotfi
Zonder, Jeffrey
Tsao, L. Claire
Anderson, Kenneth C.
Bleickardt, Eric
Singhal, Anil K.
Lonial, Sagar
BLOOD, 2014, 124 (21)
[25] TANESPIMYCIN AND BORTEZOMIB IN PATIENTS WITH RELAPSED AND RELAPSED AND REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE 1/2 STUDY
Richardson, P. G.
Chanan-Khan, A.
Lonial, S.
Krishnan, A.
Carroll, M.
Alsina, M.
Albitar, M.
Berman, D.
Szatrowski, T.
Kaplita, S.
Anderson, K. C.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 152 - 153
[26] Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup
Cohen, Adam D.
Voorhees, Peter M.
Martin, Thomas G.
Lesokhin, Alexander M.
Hillengass, Jens
Kaufman, Jonathan L.
Schecter, Jordan Mark
De Braganca, Kevin C.
Varsos, Helen
Corsale, Christina
Mistry, Pankaj
Song, Qingxuan
Koneru, Mythili
Akram, Muhammad
Costa Filho, Octavio
Einsele, Hermann
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[27] Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Martin, Thomas
Usmani, Saad Z.
Berdeja, Jesus G.
Agha, Mounzer
Cohen, Adam D.
Hari, Parameswaran
Avigan, David
Deol, Abhinav
Htut, Myo
Lesokhin, Alexander
Munshi, Nikhil C.
O'Donnell, Elizabeth
Stewart, A. Keith
Schecter, Jordan M.
Goldberg, Jenna D.
Jackson, Carolyn C.
Yeh, Tzu-Min
Banerjee, Arnob
Allred, Alicia
Zudaire, Enrique
Deraedt, William
Olyslager, Yunsi
Zhou, Changwei
Pacaud, Lida
Madduri, Deepu
Jakubowiak, Andrzej
Lin, Yi
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1265 - +
[28] Updated results from CARTITUDE-1: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM)
Jagannath, Sundar
Berdeja, Jesus G.
Jakubowiak, Andrzej
Agha, Mounzer
Cohen, Adam
Madduri, Deepu
Hari, Parameswaran
Yeh, Tzu-Min
Olyslager, Yunsi
Banerjee, Arnob
Jackson, Carolyn C.
Allred, Alicia
Zudaire, Enrique
Deraedt, William
Wu, Xiaoling
Pacaud, Lida
Akram, Muhammad
Lin, Yi
Martin, Thomas
Usmani, Saad Z.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S15 - S16
[29] CARTITUDE-1: Two-Year Post Last Patient in (LPI) Results From the Phase 1b/2 Study of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Usmani, Saad Z.
Martin, Thomas
Berdeja, Jesus G.
Jakubowiak, Andrzej
Agha, Mounzer
Cohen, Adam D.
Deol, Abhinav
Htut, Myo
Lesokhin, Alexander
Munshi, Nikhil C.
O'Donnell, Elizabeth
Jackson, Carolyn C.
Yeh, Tzu-min
Banerjee, Arnob
Zudaire, Enrique
Madduri, Deepu
Zhou, Changwei
Pacaud, Lida
Lin, Yi
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S410 - S411
[30] Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma (vol 37, pg 1779, 2021)
Martin, Tom
Usmani, Saad Z.
Schecter, Jordan M.
Vogel, Martin
Jackson, Carolyn C.
Deraedt, William
Tian, Hong
Yeh, Tzu-min
Banerjee, Arnob
Pacaud, Lida
Garrett, Ashraf
Haltner, Anja
Cameron, Chris
Van Sanden, Suzy
Diels, Joris
Valluri, Satish
Samjoo, Imtiaz A.
CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (12) : 2197 - 2208

← 1 2 3 4 5 →